Financial Performance - 4Q 2025 operating revenue was $49.3 billion, a 10% increase from the prior year, while FY 2025 revenue reached $197.6 billion, up 13%[6] - 4Q 2025 diluted EPS was $2.47, with adjusted diluted EPS at $3.33; FY 2025 diluted EPS was $25.21, and adjusted diluted EPS was $30.29[6] - Projected FY 2026 GAAP diluted EPS is expected to be at least $22.30, with adjusted diluted EPS projected to be at least $25.50[6] - Total operating revenue rose by 9.6% to $49,311 million for Q4 2025, with a total of $197,584 million for the full year, reflecting a 12.8% increase[39] - Adjusted Operating Gain for 2025 was $7.5 billion, with a guidance of at least $6.8 billion for 2026[61] - GAAP Diluted EPS for 2025 was $25.21, with a forecast of at least $22.30 for 2026[61] Segment Performance - Operating revenue for the Health Benefits segment was $41.8 billion in 4Q 2025, an 11% increase year-over-year, and $167.1 billion for FY 2025, also an 11% increase[17] - Carelon's operating revenue was $18.7 billion in 4Q 2025, a 27% increase compared to the prior year, and $71.7 billion for FY 2025, a 33% increase[24] - Operating revenue for the CarelonRx segment increased by 16.7% to $11,644 million in Q4 2025, with a full-year revenue of $43,400 million, up 20.7%[45] - Total Health Benefits Operating Revenue for the twelve months ended December 31, 2025, was $167,094 million, reflecting an 11.2% increase from $150,275 million in 2024[49] Membership and Enrollment - Medical membership totaled approximately 45.2 million as of December 31, 2025, a decrease of 0.5 million, or 1%, year-over-year[18] - Total medical membership decreased by 1.1% year-over-year to 45,232,000 members as of December 31, 2025[37] - Medicare Advantage membership grew by 7.9% year-over-year to 2,230,000 members, while total Medicare membership increased by 5.2% to 3,112,000[37] - Year-End Medical Enrollment for 2025 was 45,232,000, projected to decrease to between 43,175,000 and 43,875,000 for 2026[63] - Commercial Fee-Based enrollment for 2025 was 27,092,000, expected to increase to between 27,200,000 and 27,500,000 for 2026[63] Expenses and Claims - The benefit expense ratio for 4Q 2025 was 93.5%, an increase of 110 basis points year-over-year, while the full year ratio was 90.0%, up 150 basis points[10] - The benefit expense as a percentage of premiums increased to 93.5% in Q4 2025, compared to 92.4% in Q4 2024[39] - The current year medical claims paid as a percentage of current year net incurred medical claims was 89.5% for 2025, up from 88.5% in 2024[51] - The net medical claims payable at the end of 2025 was $16,781 million, up from $15,567 million at the end of 2024[51] Shareholder Returns - The company returned $4.1 billion of capital to shareholders in 2025, including share repurchases and dividends[6] - The company declared a first quarter 2026 dividend of $1.72 per share, payable on March 25, 2026[27] - For the three months ended December 31, 2025, shareholders' net income increased by 30.9% to $547 million compared to $418 million in the same period of 2024[54] - Adjusted shareholders' earnings per diluted share for the three months ended December 31, 2025, increased by 3.1% to $3.33 compared to $3.23 in 2024[54] - Adjusted shareholders' net income for the twelve months ended December 31, 2025, decreased by 11.6% to $6,804 million from $7,694 million in 2024[54] Assets and Cash Flow - Cash and cash equivalents at the end of the period increased to $9,491 million from $8,288 million year-over-year[41] - Total assets grew to $121,494 million as of December 31, 2025, compared to $116,889 million in 2024[41] - Operating Cash Flow for 2025 was $4.3 billion, with a guidance of at least $5.5 billion for 2026[61] Future Outlook - Full Year 2025 Premium Revenue was $164.6 billion, with a projected mid single digit decline for 2026[61] - Total Operating Revenue for 2025 was $197.6 billion, expected to decline in the low single digits for 2026[61] - Benefit Expense Ratio for 2025 was 90.0%, expected to increase to 90.2% +/- 50 bps for 2026[61] - Adjusted Effective Tax Rate for 2025 was 17.6%, projected to rise to between 22.0% and 24.0% for 2026[61]

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members we serve. Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Elevance became the second major insurer to predict declining revenue in 2026 on Wednesday, as for-profit payers continue to shave off members to try and recover margins. The Indianapolis-based insurer estimated its operating revenue will drop by a low-single digit percentage next year. The guidance comes one day after UnitedHealth forecast an ...

The Nasdaq led US stock futures higher on Wednesday as AI trade fervor spread ahead of the Federal Reserve’s latest policy decision and earnings from megacap techs. Contracts on the tech-heavy Nasdaq 100 (NQ=F) climbed about 0.9%, while those on the Dow Jones Industrial Average (YM=F) hovered below the flat line. S&P 500 futures (ES=F) moved up 0.3% on the heels of an all-time closing high. Techs are set to buoy markets again as a surprise record surge in orders for ASML's (ASML) chipmaking machines sto ...

Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) ...

每经AI快讯，1月27日，美国医保保险公司股价盘前下跌。Humana跌17%，Elevance Health跌8%， Centene跌7.7%，Molina Healthcare跌7.3%。 ...

美国政府周一表示，已提议明年向保险公司支付的医疗保险（Medicare）费用平均仅增加0.09%，医疗 保险公司股价下跌超过10%。美国医疗保险与医疗补助服务中心（CMS）表示，该提案将在2027年为医 疗保险优势项目（Medicare Advantage）额外支付7亿多美元。医疗保险公司联合健康、CVS和Humana 股价在盘后交易中下跌了近12%，Elevance Health和Molina Healthcare的股价下跌了近5%。 （文章来源：第一财经） ...

Core Viewpoint - Elevance Health (ELV) is expected to report a quarterly earnings per share (EPS) of $3.07, reflecting a decline of 20.1% year-over-year, while revenues are forecasted to increase by 10.1% to $49.53 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower in the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Projections - Analysts predict 'Revenues- Service fees' at $2.13 billion, a year-over-year increase of 4.7% [5]. - 'Revenues- Premiums' are estimated at $40.69 billion, reflecting a 12.3% year-over-year increase [5]. - 'Revenues- Net investment income' is expected to reach $469.69 million, indicating a decline of 10.9% year-over-year [5]. - 'Revenues- Product revenue' is projected at $6.82 billion, a 1.5% year-over-year increase [6]. Membership Metrics - Total Medical Membership is projected to be 45.40 million, down from 45.73 million in the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is estimated at 2.24 million, up from 2.07 million year-over-year [7]. - 'Medical Membership - Medicaid' is expected to be 8.60 million, down from 8.92 million year-over-year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.63 million, slightly down from 1.66 million year-over-year [8]. - Total Medicare membership is expected to reach 3.11 million, up from 2.96 million year-over-year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is estimated at 1.33 million, up from 1.29 million year-over-year [9]. - 'Benefit Expense Ratio' is forecasted to be 93.4%, compared to 92.4% year-over-year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.08 million, down from 27.20 million year-over-year [9]. Stock Performance - Elevance Health shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [10]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [10].

Key Takeaways Elevance Health's Q4 EPS is expected at $3.10, down 19.3% year over year, even as revenues rise 10.2%.ELV's premiums are projected to jump 12.3%, with product revenues up 1.5%, supporting Q4 sales growth.ELV faces margin pressure from higher benefit ratios and rising operating expenses.Elevance Health, Inc. (ELV) is set to report its fourth-quarter 2025 results on Jan. 28, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged ...

BRISBANE, Australia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (ASX:ELV; NASDAQ:ELVR; OTCQB:SYAXF) (“Elevra” or “Company”) advises that the Company’s December 2025 Quarterly Activities Report is scheduled for release on Wednesday, 28 January 2026 AEDT (Sydney, Melbourne). The Company will host an investor webcast covering the December 2025 Quarterly results commencing at 10.30am AEDT (Sydney, Melbourne) on Wednesday 28 January 2026. Retail shareholders and inve ...